Aspira Women's Health (AWH) Stock Price, News & Analysis

Company Overview

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs and proteins; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.

Key Stats

• Today's Range: $0.71 to $0.81
• 50-Day Range: $0.70 to $1.07
• 52-Week Range: $0.67 to $5.65
• Volume: 127,954 shs
• Average Volume: 76,259 shs
• Market Capitalization: $12.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.40
• Consensus Rating: Moderate Buy

Aspira Women's Health Stock Analysis - MarketRank™

Aspira Women's Health scored higher than 49% of companies evaluated by MarketBeat, and ranked 647th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Aspira Women's Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Aspira Women's Health has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aspira Women's Health are expected to grow in the coming year, from ($1.07) to ($0.57) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aspira Women's Health is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aspira Women's Health is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.76% of the float of Aspira Women's Health has been sold short.

Short Interest Ratio / Days to Cover

Aspira Women's Health has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Aspira Women's Health has recently decreased by 11.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Aspira Women's Health does not currently pay a dividend.

Dividend Growth

Aspira Women's Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.76% of the float of Aspira Women's Health has been sold short.

Short Interest Ratio / Days to Cover

Aspira Women's Health has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Aspira Women's Health has recently decreased by 11.82%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.95

News Sentiment

Aspira Women's Health has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Aspira Women's Health this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aspira Women's Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.30% of the stock of Aspira Women's Health is held by insiders.

Percentage Held by Institutions

Only 12.19% of the stock of Aspira Women's Health is held by institutions.

AWH Stock Analysis - Frequently Asked Questions

How have AWH shares performed this year?

Aspira Women's Health's stock was trading at $4.08 at the beginning of 2024. Since then, AWH shares have decreased by 82.2% and is now trading at $0.7278.
View the best growth stocks for 2024 here.

How were Aspira Women's Health's earnings last quarter?

Aspira Women's Health Inc. (NASDAQ:AWH) announced its earnings results on Monday, August, 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. The company had revenue of $2.42 million for the quarter, compared to analyst estimates of $2.60 million.

When did Aspira Women's Health's stock split?

Aspira Women's Health's stock reverse split on Friday, May 12th 2023. The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Aspira Women's Health's major shareholders?

Top institutional shareholders of Aspira Women's Health include B. Riley Wealth Advisors Inc. (1.90%) and Pine Valley Investments Ltd Liability Co (0.19%). Insiders that own company stock include Nicole Sandford, Veronica Gh Jordan, Minh Hoang Merchant, Valerie Barber Palmieri, Ryan Thinh Phan and Torsten Hombeck.
View institutional ownership trends.

How do I buy shares of Aspira Women's Health?

Shares of AWH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Aspira Women's Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aspira Women's Health investors own include Tesla (TSLA), Moderna (MRNA), Plug Power (PLUG), Riot Platforms (RIOT), Himax Technologies (HIMX) and HIVE Digital Technologies (HIVE).

Company Calendar

• Last Earnings: 8/12/2024
• Today: 12/27/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AWH
• CUSIP: N/A
• CIK: 926617
• Web: www.aspirawh.com
• Phone: 512-519-0400
• Fax: 512-439-6908
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.40
• High Stock Price Target: $5.50
• Low Stock Price Target: $3.30
• Potential Upside/Downside: +478.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-16,690,000.00
• Net Margins: -165.07%
• Pretax Margin: -165.07%
• Return on Equity: N/A
• Return on Assets: -267.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.75
• Quick Ratio: 0.70

Sales & Book Value

• Annual Sales: $8.96 million
• Price / Sales: 1.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.23) per share
• Price / Book: -3.31

Miscellaneous

• Outstanding Shares: 16,667,000
• Free Float: 15,950,000
• Market Cap: $12.68 million
• Optionable: No Data
• Beta: 1.39